Bryostatin-1 has the potential to improve the response rate and durability of a wide range of immuno-oncology drugs and technologies. To maximize the compound’s therapeutic and commercial utility, the company plans to collaborate with academic organizations, biopharmaceutical companies and NIH to enhance the efficacy of their immuno-oncology compounds. Similarly, the company expects to enter collaborations and partnerships to develop a functional cure for HIV using bryostatin analogs to activate latent HIV infected cells.